GATINEAU, QC --(Marketwired - May 16, 2017) - The Hydropothecary Corporation
(TSX VENTURE: THCX) ("THCX" or the "Company") is pleased to announce that it has resumed selling
cannabis products from certain lots after completion of additional testing following the Company's previously announced voluntary
stop-sale on its products.
Lot retesting was carried out to ensure there was no presence of myclobutanil, a pesticide approved for use in agriculture
(e.g. apples trees, almonds, strawberries, vegetables, soybeans and grape vines), but not for use on cannabis. Results of the
lots now released for sale show no sign of contamination. Health Canada has been provided with these test results. The Company
will continue to test product using its previously implemented voluntary testing program and is supportive of Health Canada's
mandatory testing initiative announced on May 5, 2017. The Company will continue to keep patients informed and updated on test
results. With the resumed selling, the Company currently has 13 of 14 products available for sale. Registered clients can order
their products as normal, through the webstore or by calling the Company's 24/7 line at 1-844-406-1852. Those wishing to register
can do so online or by calling the Company.
"Hydropothecary has always put our customers' health and safety first, through providing well grown and rigorously tested
medical cannabis of the highest quality. Today's announcement that we have lifted the voluntary stop-sale is a direct result of
our quality assurance efforts. We will continue to strive for the highest possible standards for all of our products and to put
patients first," said Sebastien St-Louis, Co-founder and CEO.
Based on the completion of other, additional screening, the Company is currently voluntarily recalling fourteen lots of
medical cannabis, which were supplied between February 1, 2016 and May 1, 2017, due to the detection of myclobutanil. These
products have tested positive for trace amounts over 0.01 parts per million, but no more than 0.08 parts per million. The
recalled lots are lots numbered 45, 46, 47, 54, 58, 59, 102, 109, 123, 127, 128, 129, 148 and 150.
Health Canada has deemed this a Type III recall, defined as "a situation in which the use of, or exposure to a product is not
likely to cause any adverse health consequences." All affected clients are being notified.
The source of the contamination is unknown at this time, however the Company is carrying out an in-depth investigation and has
completed sampling across its facility. A total of 254 samples have been sent for independent testing, including live plants
(flowering, vegetating, mothers), previously-tested dried cannabis lots, production inputs, cultivation equipment, and grow area
wall scrapings. Initial results indicate the contamination occurred during older production, but has not exceeded 0.08 parts per
million.
In addition, the Company is conducting additional screening on all lots produced since Hydropothecary's inception, as part of
its commitment to the highest health and safety standards.
"We will remain resolute in ensuring that our clients have the utmost confidence in all Hydropothecary products and will keep
everyone informed of our findings through our daily updates" Mr. St-Louis said.
About The Hydropothecary Corporation
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical marijuana licensed by Health
Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown
and rigorously tested medical marijuana of uncompromising quality. Hydropothecary's branding, marijuana product offering, patient
service standards and product pricing are consistent with THCX's positioning as a premium brand for a legal source for medical
marijuana within this new marketplace. In addition to medical marijuana production and sales, Hydropothecary explores various
research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is
investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export
of medical marijuana.
Forward-Looking Information
This press release contains forward-looking information which involves known and unknown risks, uncertainties and other
factors that may cause actual events to differ materially from current expectations. Important factors that could cause actual
results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention
or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.